Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC
Adding PARP inhibition to first-line abiraterone (Zytiga) reduced the risk of radiographic progression or death in metastatic castration-resistant prostate cancer (mCRPC), a pair of phase III studies showed. In PROpel, patients who received olaparib (Lynparza) along with abiraterone plus prednisone had a roughly 8-month improvement in median radiographic progression-free survival (rPFS) versus those assigned placebo […]
Common household cleaner can boost effort to harvest fusion energy on Earth
Scientists have found that adding a common household cleaning agent — the mineral boron contained in such cleaners as Borax — can vastly improve the ability of some fusion energy devices to contain the heat required to produce fusion reactions on Earth the way the sun and stars do. Physicists at the U.S. Department of […]
Mixed Results With RT Plus Short-Term ADT in Intermediate-Risk Prostate Cancer
CHICAGO — Adding a short course of androgen deprivation therapy (ADT) to dose-escalated radiotherapy (RT) led to a mixed bag of outcomes in intermediate-risk prostate cancer, according to a large randomized trial. The addition of 6 months of ADT did not improve overall survival (OS) compared with RT alone, but the hormonal therapy was associated […]
Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancer
Adding the CDK 4/6 inhibitor ribociclib (Kisqali) to a first-line hormonal treatment prolonged survival by more than 1 year in postmenopausal women with HR-positive/HER2-negative (HR+HER2-) advanced breast cancer, according to results from the MONALEESA-2 trial. Final overall survival (OS) results showed that patients treated with ribociclib plus the aromatase inhibitor (AI) letrozole (Femara) achieved a […]
Practice-Changing Study in Advanced Cervical Cancer
Adding pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) significantly slowed progression of metastatic cervical cancer and improved overall survival (OS), investigators in a randomized trial concluded. Median progression-free survival (PFS) improved from 8.2 months with chemotherapy plus or minus bevacizumab (Avastin) to 10.4 months with the addition of the PD-1 inhibitor. Comparison of […]
Chemo Triplet May Boost Survival in Rare Soft-Tissue Sarcoma
Adding temozolomide to a combination of vincristine and irinotecan (VIT) improved tumor response and survival in patients with relapsed or refractory rhabdomyosarcoma in a European phase II trial. In the trial of over 100 patients, the group who received temozolomide had a numerically improved objective response rate (ORR) after two cycles of treatment versus the […]
Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer?
Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for certain patients, long-term results of a randomized trial found. While the regimen did not prolong overall survival (OS) among all men with unfavorable-risk nonmetastatic cancer after a median of […]